Therapy of malignant pleural mesothelioma: A permanent dilemma;Die Therapie des malignen Pleuramesothelioms: Ein fortdauerndes Dilemma

Pneumologie

Volumn 53, Issue 5, 1999, Pages 266-275

  Von Bultzingslowen F ^a,b   Siemon, G ^a  

^a Krankenhaus Donaustauf   (Germany)

^b Fachklinik Donaustauf   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CYTOKINE; IMMUNOLOGIC AGENT; INTERFERON;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; GENDER; HUMAN; IMMUNOTHERAPY; LUNG RESECTION; MALIGNANT NEOPLASTIC DISEASE; MULTIMODALITY CANCER THERAPY; PHOTODYNAMIC THERAPY; PLEURA MESOTHELIOMA; PLEURECTOMY; PRIORITY JOURNAL; PROGNOSIS; PUNCTURE; THORACOSCOPY; TUMOR VOLUME;

MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 0033022352     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Aisner J: An overview of the approach to malignant pleural mesothelioma., meeting abstract. Lung Cancer Kongreß. Prag: 5/95.
2. Alberts AS, Falkson G et al.: Malignant pleural mesothelioma: Phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 1988; 80: 698-700
3. Alberts AS, Falkson G et al.: Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527-535
4. Antman BKH, Blum RH, Greenberger JS et al.: Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68: 356-362
5. Antman K, Shemin R, Ryan. L et al.: Malignant mesothelioma: Prognostic variables in a registry of 180 patients. The Dana-Farber Institute and Brigham and women's hospital experience over two decades. J Clin Oncol 1988; 6: 147-153
6. Ardizzoni A, Rosso R, Salvati F et al.: Activity of doxorubicin and cisplatin combinatioin chemotherapy in patients with diffuse malignant pleural mesothelioma. Cancer 1991; 67: 2984-2987
7. Ardizzoni A, Pennucci MC, Castagneto B, Mariani GL, Cinquegrana A, Magri D, Verna A, Salvati F, Rosso R: Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 1994; 17,1: 80-82
8. Baas P, Murrer L, Zoetmulder FAN et al.: Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 1997; 76: 819-826
9. Baas P, Schouwink H, Zoetmulder FAN: Malignant pleural mesothelioma. Annals of Oncology 1998; 9: 139-149
10. Baldini EH, Recht A et al.: Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997; 63: 334-338
11. Bignon J: Overview of current issues with respect to mesothelioma. Eur Respir Rev 1993; 3,11: 12-17
12. Bissett D, Macbeth FR, Cram I: The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (Royal College of Radiologists) 1991; 3, 6: 315-317
13. Boutin C, Irisson M et al.: Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 1987; 71: 205-206
14. Boutin C, Nussbaum E, Monnet I, Bignon J, Vanderschueren R, Guerin JC, Menard O, Mignot P, Dabouis G, Douillard JY: Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994; 74: 2460-2467
15. Boutin C, Rey F, Viallat JR: Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: A randomized trial of local radiotherapy. Chest 1995; 108, 3: 754-758
16. Boutin C, Schlesser M, Frenay C, Astoul Ph., Malignant pleural mesothelioma Eur Respir J 1998; 12: 972-981
17. Branscheid D, Krysa S, Bauer E, Bülzebruck H, Schirren J: Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardio-thorac Surg 1991; 5: 466-473
18. Breau JL, Boaziz C, Morère F, Sadoun D, Israel L: Chemotherapy with cisplatin, adriamycin, bleomycin and mitomycin C, combined with systemic and intrapleural hyluronidase in Stage II and III pleural mesothelioma. Eur Respir Rev 1993; 3, 11: 223-225
19. Butchart EG, Ashcroft T, Barnsley WC, Holden MP: Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976; 31: 15-24
20. Chahinian AP, Pajak TF, Holland JF et al.: Diffuse malignant mesothelioma. Ann Int Med 1982; 96: 746-755
21. Chahinian AP: Therapeutic modalities in malignant pleural mesothelioma. In: Chretien J, A Hirsch, Eds. Diseases of the pleura. New York: Masson; 1983. 224-226
22. Chahinian AP, Pajak TF, Holland JF, Green G: Adverse prognostic significance of thrombocytosis in patients with malignant mesothelioma. Proc Am Assoc Cancer Res 1984; 25: 161
23. Chahinian AP: Malignant Mesothelioma. In: Holland JF, Frei E, Bast RC et al., Eds. Cancer Medicine. Philadelphia: Lea & Febiger; 1993. 1337-1355
24. Chahinian AP, Antman M, Goutsou M et al.: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the cancer and leukemia group B. J Clin Oncol 1993; 11: 1559-1565
25. Chahinian AP, Norton L, Szrajer L et al.: Mitomycin C and cisplatin in human malignant mesothelioma xenografts in nude mice: Clinical correlation. Proc AACR 1983; 24, 597: 151
26. Christmas TI, Musk AW et al.: Phase II study of recombinant human α-interferon therapy in malignant pleural mesothelioma. Proc Am Assoc Cancer Res 1990; 31: 283
27. Constanzi J, Darzynkiewitz. Z et al.: The use of Onconase for patients with advanced malignant mesothelioma. Philadelphia: IMG 59; 1997 Abstr.
28. Curran D, Sahmoud T et al.: Prognostic factors with pleural mesothelioma: The European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 1998; 16: 145-152
29. Valle Da MJ, Penfield-Faber L, Kittle CF, Jensik RJ: Extrapleural pneumonectomy for diffuse malignant mesothelioma. Ann Thorac Surg 1986; 42: 612-618
30. Prangher Manzini De V, Brollo A, Francesci S et al.: Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993; 72: 410-417
31. Dirix LY, Meerbeck van J, Schrijvers D et al.: A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 1994; 5: 7
32. Epler GR, Gerald MXF, Gaensler AE, Carrington CB: Asbestos related disease from household exposure. Respiration 1980; 39: 229-240
33. Esandi M, Someren van C et al.: Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther 1997; 4, 4: 280-287
34. Eschwege S, Schlienger M: La radiotherapie des mesotheliomes pleuraux malins. A propos de 14 cas irradiés a doses élévées. J Radiol Electrol, Paris 1973; 54: 255-259
35. Faber LP: Current controversies in thoracic surgery. Philadelphia: WB Saunders; 1986, 80
36. Gelfand K, Kang E et al.: Mesothelioma patients administered recombinant adenoviral-based gene therapy exhibit TH1 cellular immune response. Abstract Int Mesothelioma Interest Group Meeting (IMG) Philadelphia; 1997. 55
37. Goey SH, Eggermont AM, Punt CJ, Slingerland R, Gratama JW, Oosterom R, Oskam R, Bolhis RL, Stoter G: Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase-I-II-study. Br J Cancer 1995; 72, 5: 1283-1288
38. Gridelli C, Pepe R, Airoma G et al.: Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. Tumori 1992; 78: 380-382
39. Hand A, Pelin K, Mattson K, Linnainmaa K: Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate. in vitro sensitivity studies in four human mesothelioma cell lines. Anticancer-Drugs 6,1; 77-82
40. Hasturk S, Tastepe I, Unlu M, Cetin G, Baris YI: Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. J Chemother 1996; 8, 2: 159-164
41. Herscher L, Hahn S, Pass H, Temeck B, Goldspiel B, Cook J, Okunieff P, Liebmann J: Phase-I-study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small cell lung cancer. J Clin Oncol 1998; 16/2: 635-641
42. Holsti LR, Pyrhonen S et al.: Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncol 1997; 36, 4: 397-405
43. Icli F, Karaoguz H et al.: Two dose levels of ifosfamide in malignant mesothelioma. Lung Cancer 1996; 15: 207-213
44. Jones DEC, Siver D: Peritoneal mesothelioma. Surgery 1979; 86: 556-560
45. Kelsen DP, Bajorin D et al.: Phase II trial of mitomycin in malignant mesothelioma. Proc Am Soc Clin Oncol 1985; 4: 146
46. Krarup-Hansen A, Hansen HH: Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 1991; 28: 319-330
47. Kutcher GJ, Kestler RT, Greenbladt D et al.: Technique for extrenal beam treatment of mesothelioma. Int J Radiat Oncol Biol Phys 1987; 13: 1747-1752
48. Law MR, Gregor A, Hodson ME et al.: Malignant Mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983; 52: 1981-1985
49. Lee YL, Wesley A: Statistical contributions to phase II trials in cancer: interpretation, analysis and design. Semi Oncol 1981; 8: 403-416
50. Lerner HJ, Schoenfeld DA et al.: Malignant mesothelioma. Proc Am Assoc Cancer Res 1981; 22: 527
51. Lindén C-J, Mercke C, Albrechtsson U, Johansson L, Ewers S-B: Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Eur Respir J 1996; 9: 2565-2572
52. Magri MD, Veronesi A, Foladore S et al.: Epirubicin in the treatment of malignant mesothelioma: a Phase II cooperative study. Tumori 1991; 77: 49-51
53. Magri MD, Foladore AS, Veronesi S et al.: Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. Ann Oncol 1992; 3: 237-238
54. Martensson G, Sorenson S: A phase II study of vincristine in malignant mesothelioma - a negative report. Cancer Chemother Pharmacol 1989; 24: 133-134
55. Mattson K, Breukelen Van FJM et al.: 4-Epidoxorubicin in mesothelioma: A phase II study for the EORTC Lung Cancer Cooperative Group. Lung Cancer 1988; 4 Suppl: A138
56. Mattson K, Giaccone G, Kirkpatrick A et al.: Epirubicin in malignant mesothelioma: a phase II study of the European organization for research and treatment of cancer - Lung Cancer Cooperative Group. J Clin Oncol 1992; 10: 824-828
57. Mbidde EK, Harland SJ et al.: Phase II trial of carboplatin (JM8) in the treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 1986; 18: 284-285
58. Middleton GW, Smith IE et al.: Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998; 9: 269-273
59. Mintzer DM, Kelsen D et al.: Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985; 69: 711-712
60. Nakano T, Miyake M, Takenaka M, Iwahashi N, Hada T, Higashino K: A pilot Phase II study of cisplatin, doxorubicin, and vindesine for the treatment of malignant pleural mesosthelioma. Eur Respir Rev; 3 11. 211-212
61. Ong ST, Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma: A review. J Clin Oncol;14 3. 1007-1017
62. Pass HI: Contemporary approaches in the investigation and treatment of malignant pleural mesothelioma. Chest Surg Clin N Am 1994; 4, 3: 497-515
63. Pass HI, Delaney TJ, Tochner Z et al.: Intrapleural photodynamic therapy: Results of a phase I trail. Ann Oncol 1994; 1: 28-37
64. Pass HI, Kranda K et al.: Surgically debulked malignant pleural mesothelioma: Result and prognostic factors. Ann Surg Oncol 1996; 4, 3: 215-222
65. Pass HI, Temeck BK et al.: Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997; 4, 8: 628-633
66. Pass HI, Temeck BK et al.: Preoperative Tumor volume is associated with outcome in malignant mesothelioma. J Thor Cardiovasc Surg 1998; 2: 310-318
67. Penucci MC, Aridizzoni A et al.: Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma. Cancer 1997; 5: 1897-1902
68. Perez-Soler R, Shin DM et al.: Phase I clinical and pharmacological study of liposome-entrapped NDDP (L-NDDP) administered intrapleurally (IPL) in patients with malignant pleural effusions (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1996; 15: A1572
69. Planting AST, Burg van der MEL, Goey SH, Schellens JHM, Bent van den MJ, Boer-Dennert de M, Stoter G, Verweij J: Phase-II-Study of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 1995; 5: 613-615
70. Raghaven D, Gianoutsos et al.: Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990; 8: 151-154
71. Ramael M, Bossche van der C et al.: Immunoreactivity for P-170 glycoprotein in malignant mesothelioma and non-neoplastic mesothelium with the JSB-1 monoclonal antibody. J Pathol 1992; 167: 5-8
72. Rice TW, Adelstein DJ, Kirby TJ, Saltarelli MG, Van-Kirk MA, Wiedemann HP, Weick JK: Aggressive multimodality therapy for malignant mesothelioma. Ann Thorac Surg 1994; 58,1: 24-29
73. Ris HB, Altermatt HJ, Nachbur B et al.: Intraoperative photodynamic therapy with mTHPC for chest malignancies. Las Surg Med 1996; 18: 39-45
74. Robinson BWS: Development of new therapeutic strategies for mesothelioma. Lung Cancer 1993; 9: 413-418
75. Ruffie P, Feld R, Minkin S et al.: Diffuse malignant mesothelioma of the pleura in Ontario and Quebec; a retrospective study of 332 patients. J Clin Oncol 1989; 8: 1157-1168
76. Ruffie P: Mesothelioma chemotherapy. Eur Respir Rev 1993; 3, 11: 199-203
77. Rusch VW, Piantadosi SP, Homes EC: The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J Thor Cardiovasc Surg 1991; 102: 1-9
78. Rusch VW, Saltz L, Venkatraman E. Ginsberg R, McCormack P, Burt M, Markman M, Kelsen D: A phase II trial of pleurectomy/ decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994; 12, 6: 1156-1163
79. Rusch VW: A proposed new international TNM Staging System for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996; 14: 1-12
80. Samoud T, Postmus PE et al.: Etoposide in malignant mesothelioma: Phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer; 1997 submitted
81. Sauter ER, Langer C, Coia LR, Goldberg M, Keller SM: Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 1995; 60, 2: 100-105
82. Schiebe MW, Hoffmann W, Kortmann RD, Bamberg M: Klinik und Therapie des malignen Pleuramesothelioms. Strahlenther Onkol 1994; 170, 11: 628-635
83. Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Walsh MHG, Komaki R, McMurtrey J, Waun-Ki-Hong L: Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin unrespectable of metastatic malignant pleural mesothelioma. Cancer 1995; 76, 11: 2230-2236
84. Schouwink JH, Korse CM, Bonfrer JGM, Baas P: Cyfra 21-1 a useful marker in malignant mesothelioma XXIV Meet. Int Soc Onco-development Biol. Med; 1996. 98 and submitted to Chest (abstr.)
85. Smythe WR, Kaiser LR et al.: Successful adenovirus-mediated gene transfer in an invivo model of human malignant mesothelioma. Ann Thorac Surg 1994; 57: 1395-1401
86. Solheim OP, Saeter G et al.: High dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992; 65: 956-960
87. Sorensen PG, Bach et al. F: Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant mesothelioma. Cancer Treat Rep 1985; 69: 1431-1432
88. Stewart DJ, Gertler SZ, Tomiak A, Shamij F, Goel R, Evans WK: High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases. Lung Cancer 1994; 11: 251-258
89. Sugarbaker DJ, Heher EC, Lee TH et al.: Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991; 102: 10-15
90. Sugarbaker D, Harpole D, Healey E, DeCamp M, Mentzer S, Liptay M, Strauss G, Swanson S, Antman K: Multimodality treatment of malignant pleural mesothelioma (MPM): results in 94 consecutive patients (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1995; 14: A1083
91. Sugarbaker D, Norberto JJ, Swanson SJ: Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma. Sem Thorac Cardiovasc Surg 1997; 9, 4: 373-382
92. Takita H, Dougherty TJ: Intracavitary photodynamic therapy for malignant pleural mesothelioma. Sem Surg Oncol 1995; 11, 5: 368-371
93. Tammilehto L, Maasilta P, Wäntylä M et al.: Oral etoposide in the treatment of malignant mesothelioma. A phase-II-study. Ann Oncol 1994; 5: 949-950
94. Tansan S, Emri S, Selcuk T, Koc Y, Hesketh P, Heeren T, McCaffrey RP, Baris YI: Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 1994; 51, 4: 348-351
95. Tortoriello A, Faccini G, Caponigro F, Maiorino L, Persico G, laffaioli RV: Interesting clinical responses in pleuric mesothelioma with two following therapeutic regimes. Proceedings of SOMPS. Fifth Congress; 1995. 255
96. Tsavaris N, Mylonakis N, Karvounis N, Bacoyiannis C, Briasoulis E et al.: Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 1994; 11: 299-303
97. Upham JW, Musk AW, Hazel van G, Byrne M, Robinson BW: Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med 1993; 23, 6: 683-687
98. Meerbeeck Van JP: Prognostic factors in malignant mesothelioma: where do we go from here? Eur Respir J7: 1029-1031
99. Meerbeeck Van J, Debruyne C et al.: Paclitaxel for malignant mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996; 74: 961-963
100. Vogelzang NJ, Goutsou S et al.: Carboplatin in malignant mesothelioma: A phase II study of CALGB. Proc Am Soc Clin Oncol 1989; 8: 321
101. Vogelzang NJ: Malignant Mesothelioma: Diagnostic and Management Strategies for 1992. Seminars in Onkology 1992; 19 No. 4: 64-71
102. Vogelzang NJ, Hernod JE et al.: Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 1997; 79, 11: 2237-2242
103. Warloe T, Heyerdahl H, Peng Q et al.: Photodynamic therapy of malignant mesothelioma of the pleura. SPIE 1994; 2371: 166-170
104. Zidar BL, Metch B, Balcerzak SP et al.: A Phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. Cancer 1992; 70: 2547-2551